新加坡国立大学Lin-Fa Wang、Danielle E. Anderson等研究人员，合作开发出一种基于抗体介导的ACE2-突刺蛋白相互作用阻断的SARS-CoV-2病毒中和测试方法。相关论文于2020年7月23日在线发表于《自然—生物技术》。
Title: A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
Author: Chee Wah Tan, Wan Ni Chia, Xijian Qin, Pei Liu, Mark I.-C. Chen, Charles Tiu, Zhiliang Hu, Vivian Chih-Wei Chen, Barnaby E. Young, Wan Rong Sia, Yee-Joo Tan, Randy Foo, Yongxiang Yi, David C. Lye, Danielle E. Anderson, Lin-Fa Wang
Abstract: A robust serological test to detect neutralizing antibodies to SARS-CoV-2 is urgently needed to determine not only the infection rate, herd immunity and predicted humoral protection, but also vaccine efficacy during clinical trials and after large-scale vaccination. The current gold standard is the conventional virus neutralization test requiring live pathogen and a biosafety level 3 laboratory. Here, we report a SARS-CoV-2 surrogate virus neutralization test that detects total immunodominant neutralizing antibodies targeting the viral spike (S) protein receptor-binding domain in an isotype- and species-independent manner. Our simple and rapid test is based on antibody-mediated blockage of the interaction between the angiotensin-converting enzyme 2 (ACE2) receptor protein and the receptor-binding domain. The test, which has been validated with two cohorts of patients with COVID-19 in two different countries, achieves 99.93% specificity and 95–100% sensitivity, and differentiates antibody responses to several human coronaviruses. The surrogate virus neutralization test does not require biosafety level 3 containment, making it broadly accessible to the wider community for both research and clinical applications.